Last news
Tarena to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 27, 2023

Tarena to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 27, 2023

...

The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial

The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial

...

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

...

The 7th Design Intelligence Award Global Ceremony - 2022 Award Ceremony & 2023 Call for Entry Launched

The 7th Design Intelligence Award Global Ceremony - 2022 Award Ceremony & 2023 Call for Entry Launched

...

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

...

SK Chemicals to Take the Lead in the $7.6 Billion Recycled PET Market

SK Chemicals to Take the Lead in the $7.6 Billion Recycled PET Market

...

Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD

Ark Biopharmaceutical and Calibr, a Division of Scripps Research, Announce Co-development Collaboration on AK0705, a Potential First-in-Class Drug for Treating a Broad Spectrum of Respiratory Diseases, Including COPD

...

ZTO Reports Fourth Quarter 2022 and Full Year 2022 Unaudited Financial Results

ZTO Reports Fourth Quarter 2022 and Full Year 2022 Unaudited Financial Results

...

menu
menu